Stacey Gundry
Concepts (358)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 64 | 2001 | 736 | 1.430 |
Why?
| | Transplantation, Heterologous | 19 | 2000 | 194 | 0.720 |
Why?
| | Heart Arrest, Induced | 8 | 1998 | 34 | 0.510 |
Why?
| | Graft Rejection | 31 | 2001 | 540 | 0.450 |
Why?
| | Tissue Donors | 11 | 1997 | 424 | 0.370 |
Why?
| | Myocardial Reperfusion | 3 | 1995 | 59 | 0.300 |
Why?
| | Heart Defects, Congenital | 16 | 2000 | 914 | 0.270 |
Why?
| | Coronary Disease | 5 | 1998 | 386 | 0.270 |
Why?
| | Pericardium | 3 | 1997 | 62 | 0.260 |
Why?
| | Esophageal Perforation | 2 | 1996 | 15 | 0.230 |
Why?
| | Graft Survival | 14 | 2000 | 526 | 0.230 |
Why?
| | Heart Valve Prosthesis | 4 | 1997 | 134 | 0.220 |
Why?
| | Coronary Artery Bypass | 3 | 1998 | 269 | 0.200 |
Why?
| | Coronary Vessels | 4 | 1997 | 251 | 0.200 |
Why?
| | Cardiac Catheterization | 4 | 1998 | 560 | 0.180 |
Why?
| | Echocardiography | 9 | 1998 | 652 | 0.170 |
Why?
| | Cardiopulmonary Bypass | 6 | 1998 | 221 | 0.170 |
Why?
| | Infant | 44 | 2001 | 10039 | 0.170 |
Why?
| | Papio | 16 | 2000 | 85 | 0.160 |
Why?
| | Sternum | 2 | 1998 | 27 | 0.160 |
Why?
| | Reoperation | 12 | 2001 | 631 | 0.160 |
Why?
| | Postoperative Complications | 18 | 2000 | 2920 | 0.160 |
Why?
| | Infant, Newborn | 37 | 2001 | 6434 | 0.160 |
Why?
| | Aortic Valve | 3 | 1998 | 365 | 0.160 |
Why?
| | Zebrafish | 3 | 2018 | 528 | 0.160 |
Why?
| | Cardiac Surgical Procedures | 6 | 2000 | 609 | 0.150 |
Why?
| | Iatrogenic Disease | 2 | 1997 | 76 | 0.150 |
Why?
| | Graft Occlusion, Vascular | 2 | 1998 | 42 | 0.140 |
Why?
| | Cardioplegic Solutions | 3 | 1995 | 6 | 0.140 |
Why?
| | Thoracotomy | 2 | 1998 | 83 | 0.140 |
Why?
| | Time Factors | 24 | 2000 | 7183 | 0.140 |
Why?
| | Echocardiography, Doppler, Color | 1 | 1997 | 38 | 0.130 |
Why?
| | Microsurgery | 1 | 1998 | 72 | 0.130 |
Why?
| | Methotrexate | 10 | 2000 | 240 | 0.130 |
Why?
| | Ventricular Outflow Obstruction | 2 | 1996 | 40 | 0.130 |
Why?
| | Tetralogy of Fallot | 2 | 1998 | 76 | 0.130 |
Why?
| | RNA, Ribosomal | 1 | 2018 | 168 | 0.130 |
Why?
| | DEAD-box RNA Helicases | 1 | 2018 | 90 | 0.130 |
Why?
| | Immunosuppressive Agents | 13 | 2000 | 847 | 0.130 |
Why?
| | Swine | 12 | 2000 | 833 | 0.120 |
Why?
| | Follow-Up Studies | 17 | 1998 | 5417 | 0.120 |
Why?
| | Child, Preschool | 31 | 2001 | 11799 | 0.120 |
Why?
| | Coronary Circulation | 2 | 1996 | 136 | 0.120 |
Why?
| | Pulmonary Valve | 2 | 1996 | 101 | 0.120 |
Why?
| | Fundoplication | 1 | 1995 | 54 | 0.110 |
Why?
| | Fontan Procedure | 1 | 1997 | 191 | 0.110 |
Why?
| | Survival Rate | 12 | 2000 | 2092 | 0.110 |
Why?
| | Protein Biosynthesis | 1 | 2018 | 458 | 0.110 |
Why?
| | Organ Transplantation | 1 | 1997 | 248 | 0.110 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2013 | 5 | 0.100 |
Why?
| | Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2013 | 9 | 0.100 |
Why?
| | Lymphocyte Subsets | 4 | 1996 | 83 | 0.100 |
Why?
| | Hypoplastic Left Heart Syndrome | 4 | 1998 | 120 | 0.100 |
Why?
| | Splenectomy | 5 | 2000 | 65 | 0.090 |
Why?
| | Zebrafish Proteins | 2 | 2018 | 311 | 0.090 |
Why?
| | Heart Ventricles | 4 | 2000 | 760 | 0.090 |
Why?
| | Humans | 71 | 2013 | 144957 | 0.090 |
Why?
| | Muscle, Skeletal | 3 | 2018 | 1796 | 0.090 |
Why?
| | Animals | 32 | 2018 | 38109 | 0.080 |
Why?
| | Dystroglycans | 1 | 2011 | 6 | 0.080 |
Why?
| | Muscular Dystrophies | 1 | 2011 | 30 | 0.080 |
Why?
| | Heart Diseases | 3 | 1993 | 350 | 0.080 |
Why?
| | Child | 29 | 2001 | 22657 | 0.080 |
Why?
| | Macaca mulatta | 7 | 2000 | 191 | 0.070 |
Why?
| | Mutation, Missense | 1 | 2011 | 340 | 0.070 |
Why?
| | Tissue and Organ Procurement | 6 | 1997 | 346 | 0.070 |
Why?
| | Animals, Newborn | 9 | 2000 | 902 | 0.070 |
Why?
| | Cyclosporine | 10 | 2000 | 265 | 0.070 |
Why?
| | Myocardium | 7 | 1998 | 939 | 0.070 |
Why?
| | Aorta, Thoracic | 3 | 2000 | 286 | 0.070 |
Why?
| | Heart Failure | 3 | 2000 | 2323 | 0.070 |
Why?
| | Organ Preservation | 3 | 1993 | 130 | 0.070 |
Why?
| | Endothelium, Vascular | 5 | 2000 | 965 | 0.060 |
Why?
| | Mitral Valve | 2 | 1998 | 96 | 0.060 |
Why?
| | Proteins | 1 | 2013 | 1022 | 0.060 |
Why?
| | Thoracic Injuries | 2 | 2000 | 73 | 0.060 |
Why?
| | Survival Analysis | 9 | 1998 | 1385 | 0.060 |
Why?
| | Tacrolimus | 5 | 1997 | 196 | 0.060 |
Why?
| | Transplantation, Homologous | 6 | 2001 | 415 | 0.060 |
Why?
| | Angioplasty, Balloon, Coronary | 2 | 1998 | 158 | 0.060 |
Why?
| | Hemodynamics | 6 | 2000 | 1121 | 0.060 |
Why?
| | Ventricular Function, Left | 5 | 1995 | 541 | 0.060 |
Why?
| | Heart | 3 | 1995 | 636 | 0.060 |
Why?
| | Aged | 10 | 2000 | 25947 | 0.050 |
Why?
| | Goats | 7 | 2000 | 25 | 0.050 |
Why?
| | Male | 34 | 2011 | 72406 | 0.050 |
Why?
| | Wounds, Nonpenetrating | 2 | 2000 | 316 | 0.050 |
Why?
| | Blood | 2 | 1995 | 109 | 0.050 |
Why?
| | Female | 33 | 2011 | 78376 | 0.050 |
Why?
| | Resuscitation | 2 | 1997 | 302 | 0.050 |
Why?
| | Equipment Design | 2 | 1998 | 530 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 2 | 1996 | 561 | 0.050 |
Why?
| | Carbon Dioxide | 2 | 1996 | 242 | 0.050 |
Why?
| | Retrospective Studies | 19 | 2001 | 17101 | 0.050 |
Why?
| | Adolescent | 15 | 2001 | 22453 | 0.040 |
Why?
| | Treatment Outcome | 10 | 2001 | 11695 | 0.040 |
Why?
| | Aorta | 3 | 2000 | 430 | 0.040 |
Why?
| | Mitral Valve Insufficiency | 3 | 1997 | 72 | 0.040 |
Why?
| | Sheep | 3 | 1993 | 880 | 0.040 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 1995 | 342 | 0.040 |
Why?
| | Cause of Death | 4 | 1997 | 472 | 0.040 |
Why?
| | Body Temperature | 2 | 1993 | 229 | 0.040 |
Why?
| | Methylprednisolone | 6 | 2000 | 64 | 0.040 |
Why?
| | Cardiomyopathies | 2 | 1997 | 338 | 0.040 |
Why?
| | Heart Atria | 2 | 1992 | 144 | 0.040 |
Why?
| | Trisaccharides | 1 | 2000 | 2 | 0.040 |
Why?
| | Incidence | 6 | 2000 | 2883 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 2000 | 13 | 0.040 |
Why?
| | Antigens, Heterophile | 1 | 2000 | 5 | 0.040 |
Why?
| | Polytetrafluoroethylene | 1 | 2000 | 25 | 0.040 |
Why?
| | Aortic Rupture | 1 | 2000 | 28 | 0.040 |
Why?
| | Transplantation Chimera | 1 | 2000 | 56 | 0.040 |
Why?
| | Antilymphocyte Serum | 5 | 2000 | 61 | 0.040 |
Why?
| | Cell Line | 2 | 2018 | 2882 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4569 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2000 | 8279 | 0.040 |
Why?
| | Myocardial Contraction | 4 | 1993 | 298 | 0.040 |
Why?
| | Lymphocyte Activation | 2 | 2000 | 1126 | 0.040 |
Why?
| | Rhizopus | 1 | 1999 | 4 | 0.040 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2000 | 80 | 0.040 |
Why?
| | Lung Abscess | 1 | 1999 | 7 | 0.040 |
Why?
| | Lung Diseases, Fungal | 1 | 1999 | 13 | 0.040 |
Why?
| | Mucormycosis | 1 | 1999 | 19 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 2 | 1997 | 133 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2000 | 294 | 0.040 |
Why?
| | Oxygen | 2 | 1996 | 995 | 0.040 |
Why?
| | Cell Adhesion | 1 | 2000 | 455 | 0.040 |
Why?
| | Situs Inversus | 1 | 1998 | 3 | 0.040 |
Why?
| | Hypothermia, Induced | 2 | 1998 | 96 | 0.040 |
Why?
| | Adult | 10 | 2000 | 40506 | 0.030 |
Why?
| | Length of Stay | 2 | 1998 | 1337 | 0.030 |
Why?
| | Lymphocytes | 1 | 2000 | 382 | 0.030 |
Why?
| | PAX2 Transcription Factor | 1 | 2018 | 8 | 0.030 |
Why?
| | Cell Nucleolus | 1 | 2018 | 20 | 0.030 |
Why?
| | Age Factors | 6 | 1995 | 3335 | 0.030 |
Why?
| | Suction | 1 | 1998 | 33 | 0.030 |
Why?
| | Dermatologic Surgical Procedures | 1 | 1998 | 21 | 0.030 |
Why?
| | Hospital Mortality | 3 | 2000 | 1031 | 0.030 |
Why?
| | Feasibility Studies | 3 | 1998 | 1095 | 0.030 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 1998 | 46 | 0.030 |
Why?
| | Heart Septal Defects | 1 | 1997 | 13 | 0.030 |
Why?
| | Aortic Coarctation | 1 | 1998 | 79 | 0.030 |
Why?
| | Heart Septal Defects, Atrial | 1 | 1998 | 59 | 0.030 |
Why?
| | Myoblasts | 1 | 2018 | 84 | 0.030 |
Why?
| | Embryo, Nonmammalian | 1 | 2018 | 173 | 0.030 |
Why?
| | Death | 1 | 1998 | 131 | 0.030 |
Why?
| | Aortic Valve Insufficiency | 1 | 1997 | 43 | 0.030 |
Why?
| | Muscle Development | 1 | 2018 | 116 | 0.030 |
Why?
| | Azathioprine | 5 | 1998 | 49 | 0.030 |
Why?
| | Middle Aged | 9 | 2000 | 35928 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2018 | 250 | 0.030 |
Why?
| | Drainage | 1 | 1998 | 185 | 0.030 |
Why?
| | Vena Cava, Inferior | 1 | 1997 | 81 | 0.030 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2000 | 359 | 0.030 |
Why?
| | Actuarial Analysis | 5 | 1996 | 21 | 0.030 |
Why?
| | United Kingdom | 1 | 1997 | 338 | 0.030 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 1998 | 192 | 0.030 |
Why?
| | Surgical Flaps | 1 | 1997 | 142 | 0.030 |
Why?
| | Ethics, Medical | 1 | 1997 | 90 | 0.030 |
Why?
| | Gastric Fundus | 1 | 1996 | 3 | 0.030 |
Why?
| | Myosins | 2 | 1993 | 136 | 0.030 |
Why?
| | Patient Care Planning | 1 | 1997 | 170 | 0.030 |
Why?
| | Drug Therapy, Combination | 4 | 2000 | 1048 | 0.030 |
Why?
| | Regeneration | 1 | 2018 | 197 | 0.030 |
Why?
| | Antibodies | 2 | 1997 | 403 | 0.030 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 1998 | 197 | 0.030 |
Why?
| | Brain Death | 2 | 1993 | 60 | 0.030 |
Why?
| | Blood Pressure | 2 | 1993 | 1769 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 1998 | 320 | 0.030 |
Why?
| | T-Lymphocytes | 2 | 2000 | 1982 | 0.030 |
Why?
| | Morbidity | 1 | 1996 | 323 | 0.030 |
Why?
| | Heart-Assist Devices | 1 | 2000 | 567 | 0.030 |
Why?
| | Research | 1 | 1997 | 431 | 0.030 |
Why?
| | Pulmonary Veins | 1 | 1995 | 105 | 0.030 |
Why?
| | Arteriosclerosis | 1 | 1994 | 84 | 0.030 |
Why?
| | Persistent Fetal Circulation Syndrome | 1 | 1995 | 138 | 0.030 |
Why?
| | Bioprosthesis | 1 | 1994 | 40 | 0.030 |
Why?
| | Myosin Light Chains | 1 | 1993 | 28 | 0.030 |
Why?
| | Central Nervous System | 1 | 1996 | 281 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 1998 | 705 | 0.020 |
Why?
| | Aneurysm, False | 1 | 1993 | 45 | 0.020 |
Why?
| | Blood Gas Analysis | 1 | 1993 | 83 | 0.020 |
Why?
| | Societies, Medical | 1 | 1997 | 887 | 0.020 |
Why?
| | Prosthesis Failure | 1 | 1994 | 128 | 0.020 |
Why?
| | Heart Septum | 1 | 1992 | 28 | 0.020 |
Why?
| | Transplantation, Autologous | 1 | 1994 | 292 | 0.020 |
Why?
| | Protein Stability | 1 | 2013 | 178 | 0.020 |
Why?
| | Interleukin-6 | 1 | 1997 | 780 | 0.020 |
Why?
| | Syndrome | 2 | 1991 | 380 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1997 | 1054 | 0.020 |
Why?
| | Transposition of Great Vessels | 1 | 1992 | 41 | 0.020 |
Why?
| | California | 4 | 1997 | 475 | 0.020 |
Why?
| | Catalysis | 1 | 2013 | 322 | 0.020 |
Why?
| | Muscles | 1 | 2013 | 333 | 0.020 |
Why?
| | Body Weight | 2 | 1995 | 978 | 0.020 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 1993 | 139 | 0.020 |
Why?
| | Postoperative Care | 1 | 1993 | 288 | 0.020 |
Why?
| | Pulmonary Artery | 1 | 1997 | 1134 | 0.020 |
Why?
| | Cytomegalovirus Infections | 1 | 1993 | 206 | 0.020 |
Why?
| | Myocardial Revascularization | 1 | 1990 | 85 | 0.020 |
Why?
| | Cardiomegaly | 1 | 1992 | 174 | 0.020 |
Why?
| | Peritoneal Dialysis | 1 | 1992 | 100 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2499 | 0.020 |
Why?
| | Defibrillators, Implantable | 1 | 1994 | 382 | 0.020 |
Why?
| | Whole-Body Irradiation | 2 | 2000 | 76 | 0.020 |
Why?
| | Point Mutation | 1 | 2011 | 243 | 0.020 |
Why?
| | Decision Trees | 1 | 1990 | 81 | 0.020 |
Why?
| | HLA Antigens | 1 | 1991 | 225 | 0.020 |
Why?
| | Temperature | 1 | 1993 | 679 | 0.020 |
Why?
| | Antibody Formation | 2 | 2000 | 294 | 0.020 |
Why?
| | Lymphocyte Culture Test, Mixed | 2 | 2000 | 51 | 0.020 |
Why?
| | Mice | 2 | 2018 | 18365 | 0.020 |
Why?
| | CD2 Antigens | 2 | 2000 | 8 | 0.020 |
Why?
| | Case-Control Studies | 1 | 1996 | 3608 | 0.020 |
Why?
| | Base Sequence | 1 | 2011 | 2191 | 0.020 |
Why?
| | Emergencies | 2 | 2000 | 176 | 0.020 |
Why?
| | Guanidines | 2 | 1997 | 41 | 0.020 |
Why?
| | Mental Disorders | 1 | 1996 | 1172 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2931 | 0.020 |
Why?
| | Immunoglobulin M | 2 | 2000 | 284 | 0.020 |
Why?
| | Combined Modality Therapy | 2 | 2000 | 1268 | 0.010 |
Why?
| | Motor Activity | 1 | 2011 | 722 | 0.010 |
Why?
| | Killer Cells, Natural | 2 | 2000 | 469 | 0.010 |
Why?
| | Leukocytes | 2 | 2000 | 295 | 0.010 |
Why?
| | Preoperative Care | 3 | 1994 | 380 | 0.010 |
Why?
| | Risk Factors | 6 | 1998 | 10792 | 0.010 |
Why?
| | Cryopreservation | 2 | 1997 | 110 | 0.010 |
Why?
| | Palliative Care | 2 | 1994 | 1008 | 0.010 |
Why?
| | United States | 3 | 1997 | 15988 | 0.010 |
Why?
| | Antigens, CD | 2 | 2000 | 555 | 0.010 |
Why?
| | Forecasting | 2 | 1998 | 391 | 0.010 |
Why?
| | Myocardial Ischemia | 2 | 1999 | 285 | 0.010 |
Why?
| | Acute Kidney Injury | 1 | 1992 | 866 | 0.010 |
Why?
| | Contraindications | 2 | 1993 | 91 | 0.010 |
Why?
| | Chi-Square Distribution | 2 | 1995 | 529 | 0.010 |
Why?
| | Recurrence | 2 | 1998 | 1135 | 0.010 |
Why?
| | CD8 Antigens | 2 | 1994 | 72 | 0.010 |
Why?
| | Pediatrics | 1 | 1991 | 1115 | 0.010 |
Why?
| | Hemorrhage | 2 | 2000 | 809 | 0.010 |
Why?
| | Prognosis | 3 | 2000 | 4293 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2000 | 4155 | 0.010 |
Why?
| | CD4 Antigens | 2 | 1994 | 139 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 1994 | 1980 | 0.010 |
Why?
| | Stroke Volume | 2 | 1995 | 651 | 0.010 |
Why?
| | Mutation | 1 | 2013 | 4099 | 0.010 |
Why?
| | Cytokines | 2 | 2000 | 2065 | 0.010 |
Why?
| | Pokeweed Mitogens | 1 | 2000 | 7 | 0.010 |
Why?
| | Extracorporeal Circulation | 1 | 2000 | 15 | 0.010 |
Why?
| | Constriction | 1 | 2000 | 47 | 0.010 |
Why?
| | Paraplegia | 1 | 2000 | 61 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 2 | 1992 | 415 | 0.010 |
Why?
| | Biopsy | 2 | 1994 | 1077 | 0.010 |
Why?
| | Amphotericin B | 1 | 1999 | 37 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2000 | 1048 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 2000 | 272 | 0.010 |
Why?
| | Lymphatic Irradiation | 1 | 1998 | 10 | 0.010 |
Why?
| | Elective Surgical Procedures | 1 | 2000 | 201 | 0.010 |
Why?
| | Spleen | 1 | 2000 | 508 | 0.010 |
Why?
| | Epitopes | 1 | 2000 | 485 | 0.010 |
Why?
| | Antifungal Agents | 1 | 1999 | 149 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 851 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 2000 | 514 | 0.010 |
Why?
| | Fetal Blood | 1 | 2000 | 342 | 0.010 |
Why?
| | Cattle | 1 | 2000 | 1000 | 0.010 |
Why?
| | Prospective Studies | 3 | 1996 | 7997 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1998 | 160 | 0.010 |
Why?
| | Angioplasty, Balloon | 1 | 1998 | 94 | 0.010 |
Why?
| | Euthanasia, Passive | 1 | 1997 | 3 | 0.010 |
Why?
| | Swine, Miniature | 1 | 1997 | 89 | 0.010 |
Why?
| | Death, Sudden, Cardiac | 1 | 1998 | 230 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 1998 | 769 | 0.010 |
Why?
| | Disclosure | 1 | 1997 | 85 | 0.010 |
Why?
| | Withholding Treatment | 1 | 1997 | 81 | 0.010 |
Why?
| | Random Allocation | 1 | 1997 | 363 | 0.010 |
Why?
| | Pressure | 1 | 1997 | 225 | 0.010 |
Why?
| | Safety | 1 | 1998 | 356 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 1996 | 77 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 2000 | 893 | 0.010 |
Why?
| | Ultrasonography | 1 | 2000 | 770 | 0.010 |
Why?
| | Linear Models | 1 | 1998 | 854 | 0.010 |
Why?
| | Body Surface Area | 1 | 1995 | 35 | 0.010 |
Why?
| | Cadaver | 1 | 1997 | 304 | 0.010 |
Why?
| | Perfusion | 1 | 1997 | 250 | 0.010 |
Why?
| | Fetus | 1 | 2000 | 803 | 0.010 |
Why?
| | Pulmonary Veno-Occlusive Disease | 1 | 1995 | 11 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1996 | 266 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2000 | 1217 | 0.010 |
Why?
| | Edema | 1 | 1996 | 124 | 0.010 |
Why?
| | Cardiac Output, Low | 1 | 1995 | 54 | 0.010 |
Why?
| | Informed Consent | 1 | 1997 | 198 | 0.010 |
Why?
| | Liver Function Tests | 1 | 1995 | 106 | 0.010 |
Why?
| | Necrosis | 1 | 1996 | 244 | 0.010 |
Why?
| | Heart Valve Diseases | 1 | 1996 | 151 | 0.010 |
Why?
| | Organ Size | 1 | 1995 | 463 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1995 | 316 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 1994 | 23 | 0.010 |
Why?
| | Antigens, CD20 | 1 | 1994 | 35 | 0.010 |
Why?
| | Methods | 1 | 1994 | 69 | 0.010 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 1994 | 37 | 0.010 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1994 | 100 | 0.010 |
Why?
| | Treatment Failure | 1 | 1995 | 365 | 0.010 |
Why?
| | Cardiac Volume | 1 | 1994 | 15 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 1998 | 1718 | 0.010 |
Why?
| | Shock | 1 | 1995 | 108 | 0.010 |
Why?
| | Antigens, Surface | 1 | 1994 | 157 | 0.010 |
Why?
| | Pericardial Effusion | 1 | 1994 | 22 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1994 | 166 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1994 | 370 | 0.010 |
Why?
| | H-Y Antigen | 1 | 1993 | 11 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 1995 | 783 | 0.010 |
Why?
| | Histocompatibility | 1 | 1993 | 21 | 0.010 |
Why?
| | Emergency Medical Services | 1 | 2000 | 696 | 0.010 |
Why?
| | Receptors, Immunologic | 1 | 1994 | 206 | 0.010 |
Why?
| | Single-Blind Method | 1 | 1994 | 312 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 1995 | 264 | 0.010 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 293 | 0.010 |
Why?
| | Pulmonary Atelectasis | 1 | 1992 | 16 | 0.010 |
Why?
| | Regression Analysis | 1 | 1995 | 1003 | 0.010 |
Why?
| | Myocarditis | 1 | 1994 | 102 | 0.010 |
Why?
| | Diastole | 1 | 1993 | 143 | 0.010 |
Why?
| | Systole | 1 | 1993 | 178 | 0.010 |
Why?
| | Ventricular Function | 1 | 1992 | 57 | 0.010 |
Why?
| | Cohort Studies | 2 | 1993 | 5965 | 0.010 |
Why?
| | Prednisone | 1 | 1993 | 221 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1994 | 289 | 0.010 |
Why?
| | Erythromycin | 1 | 1991 | 20 | 0.010 |
Why?
| | Ciprofloxacin | 1 | 1991 | 26 | 0.010 |
Why?
| | Confidence Intervals | 1 | 1992 | 333 | 0.010 |
Why?
| | Transforming Growth Factor alpha | 1 | 1991 | 56 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1995 | 1540 | 0.010 |
Why?
| | Gentamicins | 1 | 1991 | 51 | 0.010 |
Why?
| | Platelet-Derived Growth Factor | 1 | 1991 | 90 | 0.010 |
Why?
| | B-Lymphocyte Subsets | 1 | 1991 | 80 | 0.010 |
Why?
| | Heart Arrest | 1 | 1995 | 407 | 0.010 |
Why?
| | Logistic Models | 1 | 1996 | 2119 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1995 | 2032 | 0.010 |
Why?
| | Drug Interactions | 1 | 1991 | 401 | 0.000 |
Why?
| | Macrophages | 1 | 1998 | 1511 | 0.000 |
Why?
| | Clinical Protocols | 1 | 1991 | 282 | 0.000 |
Why?
| | Hypertension | 1 | 1998 | 1264 | 0.000 |
Why?
| | Transforming Growth Factor beta | 1 | 1991 | 479 | 0.000 |
Why?
| | Sensitivity and Specificity | 1 | 1994 | 1990 | 0.000 |
Why?
| | Registries | 1 | 1997 | 2385 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1993 | 672 | 0.000 |
Why?
| | Communicable Diseases | 1 | 1991 | 163 | 0.000 |
Why?
| | Emergency Service, Hospital | 1 | 2000 | 2313 | 0.000 |
Why?
| | Counseling | 1 | 1991 | 408 | 0.000 |
Why?
| | Analysis of Variance | 1 | 1991 | 1311 | 0.000 |
Why?
| | Erythrocytes | 1 | 1994 | 757 | 0.000 |
Why?
| | Immunity, Innate | 1 | 1994 | 846 | 0.000 |
Why?
| | Flow Cytometry | 1 | 1991 | 1173 | 0.000 |
Why?
| | Sex Factors | 1 | 1993 | 2114 | 0.000 |
Why?
| | Myocardial Infarction | 1 | 1993 | 1209 | 0.000 |
Why?
| | Biomarkers | 1 | 1997 | 4275 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1991 | 1524 | 0.000 |
Why?
| | Quality of Life | 1 | 1996 | 3192 | 0.000 |
Why?
| | Tomography, X-Ray Computed | 1 | 1993 | 2738 | 0.000 |
Why?
| | Mass Screening | 1 | 1991 | 1348 | 0.000 |
Why?
|
|
Gundry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|